SCHEMBL11005

SCHEMBL11005

CC(=O)Nc1cc(C#Cc2cccnc2)n(C)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 3/20 0.53
ABL2 P42684 2/20 0.53
GRM5 P41594 2/20 0.50
CYP1A2 P05177 1/20 0.43
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
FFAR1 O14842 1/20 0.39
CYP2A6 P11509 1/20 0.39
CYP2C9 P11712 1/20 0.39
CHRNB2 P17787 1/20 0.39
CYP2B6 P20813 1/20 0.39
CYP2C19 P33261 1/20 0.39
CHRNA4 P43681 1/20 0.39
MAP4K4 O95819 1/20 0.39
MAPK8 P45983 1/20 0.39
CSNK1A1 P48729 1/20 0.39
CDK7 P50613 1/20 0.39
TYRO3 Q06418 1/20 0.39
LRRK2 Q5S007 1/20 0.39
AURKB Q96GD4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12710137 0.80 ABL1 (0.51) ABL1ABL2CYP2C9CLK4PIK3CA
SCHEMBL12710083 0.79 ABL1 (0.50) ABL1ABL2CYP2C9PIK3CAPIK3CG
SCHEMBL12710081 0.76 ABL1 (0.49) ABL1ABL2CYP2C9PIK3CAPIK3CG
SCHEMBL11353 0.75 CYP2A6 (0.44) GRM5CYP1A2CYP2A6CYP2C9CHRNB2
SCHEMBL10369 0.74 CYP1A2 (0.56) ABL1CYP1A2ADORA2AADORA1CYP2A6
SCHEMBL12710135 0.73 PIK3CG (0.49) ABL1ABL2FFAR1CYP2C9PIK3CA
SCHEMBL11562 0.71 GRM5 (0.42) ABL1ABL2GRM5CYP1A2CYP2A6
SCHEMBL3712399 0.69 GRM5 (0.46) GRM5CYP1A2ADORA2AADORA1
SCHEMBL22833582 0.68 CSF1R (0.58) ABL1CSF1RKIT
SCHEMBL23009368 0.67 CYP2A6 (0.51) GRM5CYP1A2FFAR1CYP2A6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488511-A1 PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE Vertex Pharmaceuticals Incorporated (US) 2012-08-22 EP disclosed
WO-2011041634-A1 PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-07 WO disclosed
WO-2011041634-A1 PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-07 WO disclosed
US-20110081316-A1 PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-07 US disclosed
US-20110081316-A1 PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081316-A1 PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CA, PIK3CD, PIK3CG ABL1 212/4885ABL2 1079/4885GRM5 2565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.